Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. As of Dec 31 2012, Co. had rights to one product, OFIRMEV® (acetaminophen) injection, an intravenous formulation of acetaminophen. The U.S. Food and Drug Administration has approved OFIRMEV, which is used for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever in adults and children two years of age and older.
|
Free CADX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.80 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |